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Acute myeloid leukemia (AML) is the most common form of acute leukemia in 
elderly patients. Over the past four decades the basic therapeutic armamentarium 
was the standard cytotoxic treatment. The new insights in understanding the patho-
genesis of AML was the momentum that revolutionized the treatment landscape 
in AML. The last five years unprecedented growth has been seen in the number of 
target therapy drugs for the treatment of AML. These new drugs did not just have 
a clinical benefit as single agents but also have improved AML patient outcomes if 
combined with conventional cytotoxic therapy. Here, we review recent advances in 
target-based therapy for patients with AML focusing on their mechanism of action 
and the results from already published clinical trials.
Keywords: acute myeloid leukemia, target therapy, FLT3 inhibitors, IDH inhibitors, 
pro-apoptotic agents, smoothened inhibitors, checkpoint inhibitors, CD33-targeted 
therapy, E-selectin inhibitors, Polo-like kinase inhibitors
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignant disease, char-
acterized by uncontrolled proliferation with impaired differentiation of myeloid 
progenitor cells and aggressive clinical course. In the past two decades the treatment 
landscape of AML underwent significant changes due to explosive growth in knowl-
edge of the molecular pathways involved in the AML origin and course evolution. 
This increased new data and understanding of the pathogenesis of AML, facilitated 
the development of new drugs in the treatment of AML, particularly the creation of 
drugs that target the disease on a molecular level. Encouraging efficacy of targeted 
therapy when combined with the traditional chemotherapy have resulted in big 
improvement to AML treatment and survival. In this chapter, we will discuss the 
drugs used in treatment of AML, including targeted treatment strategies that have 
recently entered the clinical practice.
1.1 Signaling and kinase pathway mutations inhibitors
1.1.1 FLT3 tyrosine kinase inhibitors
Full-length human FLT3 was cloned from a pre-B cell library in 1993 [1], from a 
CD34+ hematopoietic stem cell-enriched library [2], and is located on chromosome 
13q12 [3]. FLT3 is a member of class III receptor tyrosine kinases (RTK) [4] and 
its activation leads to promotion of cell survival, proliferation, and differentiation 
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through various signaling pathways, including PI3K, RAS, and STAT5 [5]. It is pres-
ent in approximately 20–30% of adult AML patients and 5–15% of pediatric AML 
patients [6, 7]. FLT3-ITD mutations are associated with higher relapse rate and 
poorer overall survival, particularly with a high ratio of mutant allelic burden [8, 9]. 
Several first- and next generation FLT3 inhibitors have been investigated in patients 
with FLT3-ITD-mutated AML.
1.1.1.1 First-generation FLT3 inhibitors
1.1.1.1.1 Midostaurin
Midostaurin (Rydapt®, Novartis Pharmaceuticals, Inc. (PKC412)) is a multiki-
nase inhibitor, targets wild type FLT3 and mutated FLT3 (ITD and tyrosine kinase 
domain (TKD)) [10]. Midostaurin also inhibits c-kit, platelet-derived growth factor 
receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), and 
protein kinase C [11]. A phase III international prospective, multinational, random-
ized, placebo-controlled, double-blind RATIFY study confirmed that, addition 
of midostaurin to standard induction chemotherapy could significantly increase 
OS vs. placebo among AML adults with FLT3 mutation (median OS of 74.7 m vs. 
25.6 m, HR = 0.78, n = 717). RATIFY enrolled adults aged 18–59 years with newly 
diagnosed FLT3-mutated (ITD or TKD) AML. Patients were stratified accord-
ing to FLT3 mutation type (TKD, ITD with a high AR [>0.7], and ITD with a low 
AR [0.05–0.7]) The addition of midostaurin demonstrated a significant survival 
benefit in patients with FLT3-mutated AML compared with placebo, with a 22% 
reduction in the rate of death compared with placebo (hazard ratio [HR], 0.78 [95% 
CI, 0.63–0.96]; P = 0.009). Although not specifically mandated, allogeneic stem 
cell transplantation (allo-SCT) was performed in 25% of patients in first complete 
remission (CR) and 57% of patients overall. Furthermore, patients receiving an 
allo-SCT in first CR had better outcome if they were treated with midostaurin dur-
ing induction therapy (P = 0.08), suggesting that the optimal treatment strategy in 
FLT3-mutated AML would be to move on to allo-SCT early in first CR [12]. Adverse 
events (AEs) occurring during treatment with midostaurin were common in 
patients receiving intensive chemotherapy for AML. The most common nonhema-
tologic grade ≥ 3 AEs were febrile neutropenia, infection, lymphopenia, diarrhea, 
and rash/desquamation. The rates of grade ≥ 3 AEs were largely similar between 
the midostaurin and placebo groups, with the exceptions of rash/desquamation and 
anemia (higher in the midostaurin group) and nausea (nearly twice as common in 
the placebo group) [12, 13]. Other, less common AEs reported with midostaurin 
included pulmonary AEs (i.e., pneumonitis or pulmonary infiltrate), cardiac AEs 
(e.g., prolonged corrected QT interval) and hepatic or renal dysfunction [12–14].
1.1.1.1.2 Sorafenib
Sorafenib is a potent first-generation multikinase inhibitor with activity against 
FLT3/ITD receptor but resistance emerges as FLT3-TKD point mutations [15]. It 
has been evaluated as either single agent or in combination with chemotherapies 
in numerous phase I and phase II clinical trials [16–20]. In an early phase clinical 
trial, sorafenib combined with idarubicin and high dose cytarabine in younger 
de novo AML patients provided a CR rate of 93% and a 1-year survival rate of 
74% in FLT3-ITD positive AML patients [18]. In SORAML study, a placebo-
controlled randomized study from Germany in 267 newly diagnosed patients aged 
18–60 years. Sorafenib was added to daunorubicin and cytarabine (7 + 3) which 
resulted in a significantly prolonged 3-year EFS (40 vs. 22%, P = 0.013) and RFS 
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(56 vs. 38%, P = 0.017) without improvement in OS and CR [21]. Another ran-
domized placebo-controlled trial in 201 older patients aged 61–80 years did not 
demonstrated improvement in EFS, CR, and OS. The results showed higher early 
mortality (17 versus 7%, P = 0.052) compared with placebo [22]. In multivariate 
analysis of retrospective study analysing the effect of sorafenib as post-transplant 
maintenance in adult patients with FLT3-internal tandem duplication (ITD) acute 
myeloid leukaemia (AML) in 26 sorafenib patients and 55 controls, sorafenib 
significantly improved OS [Hazard ratio (HR) 0·26, P = 0·021] and PFS (HR 0·25, 
P = 0·016). Also there was no difference in 2-year non-relapse mortality (9·8% 
vs. 9·3%, P = 0·82) or 1-year chronic graft-versus-host disease (55·5% vs. 37·2%, 
P = 0·28) [23]. The most common adverse events occurring during treatment with 
sorafenib in SORAML study were fever, infections, pneumonia and pain. Grade 3 or 
worse adverse events that were significantly more common in the sorafenib group 
than the placebo group were fever, diarrhea, bleeding, cardiac events, hand-foot-
skin reaction and rash [21].
1.1.1.1.3 Sunitinib
Sunitinib is an oral multitargeted kinase inhibitor with selectivity for FLT3, 
PDGFa/b, VEGF receptor, and Kit receptor tyrosine kinases [24]. Sunitinib induces 
G1 phase arrest, increases pro-apoptotic molecule expression, and decreases 
anti-apoptotic molecule expression in AML cells [25]. In a study by O’Farrell and 
colleagues in 29 AML patients each received a single dose of sunitinib, inhibition of 
FLT3 phosphorylation was observed in 50% of FLT3 wild-type patients and 100% 
of FLT3 mutated patients [26]. In another phase I study of sunitinib in 15 patients 
with refractory AML partial responses were achieved in all 4 patients with FLT3 
mutations compared with 2 of 10 in patients with wild-type FLT3. All responses 
were of short duration and the most frequent grade 2 toxicities were edema, fatigue, 
and oral ulcerations occurring with a regimen of 50 mg/week [27]. In another 
phase I/II clinical trial, sunitinib combined with intensive chemotherapy included 
22 patients older than 60 years with FLT3/ITD-mutated. Thirteen patients, includ-
ing 8 patients with FLT3/ITD mutation, achieved CR/CRi. The median overall, 
relapse-free, and event-free survival of the 17 patients were 1.6, 1.0, and 0.4 years, 
respectively [28].
1.1.1.1.4 Lestaurtinib
Lestaurtinib (CEP-701) is an orally bioavailable first generation FLT3 inhibitor. 
It is derived from the bacterial fermentation product K-252a as indolocarbazole 
alkaloid compound. Except inhibition of FLT3 Lestaurtinib also inhibits JAK2, 
tropomyosin receptor kinases and neurotrophin receptors [29–33]. In a phase 2 
trial lestaurtinib was administered as monotherapy in untreated older patients with 
AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation 
status. This study involved 29 patients with median age of 73 years. Lestaurtinib 
was administered orally at doses of 60 mg and 80 mg twice daily for 8 weeks. 
Clinical activity was evident in 8 (30%) patients, including 3 (60%) of 5 FLT3 
mutant patients and 5 (23%) of 22 evaluable FLT3 WT patients, the difference 
in response rates between mutation groups not reaching statistical significance. 
Lestaurtinib was generally well tolerated. Commonly observed toxicities included 
mild nausea (8 patients), emesis (5 patients), constipation (5 patients), diarrhea  
(6 patients), and elevations in alkaline phosphatase concentration (13 patients) [34].  
Another phase 1/2 trial in 14 heavily pretreated AML patients treated with CEP-701 
at an initial dose of 60 mg orally twice daily, showed clinical evidence of biologic 
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activity and measurable clinical response in 5 patients with significant reductions in 
bone marrow and peripheral blood blasts and minimal drug related toxicities [35]. 
A randomized assessment from UK AML 15 and AML 17 trials confirmed no statis-
tically significant benefit observed in the combination of lestaurtinib with standard 
chemotherapy for newly diagnosed AML patients mostly younger than 60 years.
1.1.1.1.5 Tandutinib
Tandutinib (MLN518) is FLT3, KIT, PDGFR and type III receptor tyrosine 
kinases inhibitor. Tandutinib induces apoptosis and inhibits FLT3/ITD phosphory-
lation, cellular proliferation, and signaling of the MAPK and PI3K pathways [36]. 
In a phase 1 trial tandutinib was given orally (from 50–700 mg twice daily) in 40 
patients with either AML or high-risk myelodysplastic syndrome (MDS) with only 
8 patients with FLT3-ITD mutations. Even among the patients with FLT3-ITD 
mutations who were treated at potentially effective doses, response evaluation was 
often not possible because of rapid disease progression, sudden disease-related 
clinical deterioration, or tandutinib-related toxicity. Tandutinib treatment was 
associated muscular weakness, nausea, vomiting and less often diarrhea [37].
1.1.1.2 Second and next generation FLT3 inhibitors
1.1.1.2.1 Quizartinib
Quizartinib (AC220) is a selective and highly potent second-generation class 
III receptor TKI that selectively inhibits FLT3/STK1, CSF1R/FMS, SCFR/KIT, and 
PDGFRs in a dose dependent manner [38]. Quizartinib was first tested in phase I 
dose-escalation trial in patients with relapsed and refractory AML patients irre-
spective of FLT3 mutation status. Quizartinib was administered orally at escalating 
doses of 12 to 450 mg/day to 76 patients, with a median of three prior therapies 
and responses occurred in 23 (30%) of 76 patients, including 10 (13%) complete 
remissions (CR). The median duration of response was 13.3 weeks and the median 
survival was 14 weeks. The most common treatment-related adverse events were 
nausea, vomiting, and prolonged QT interval. The maximum tolerated dose (MTD) 
was 200 mg/day, and the dose-limiting toxicity was grade 3 QT prolongation 
[39]. In another 2-part, phase 1, multicenter, open-label, sequential group dose-
escalation trial of quizartinib in combination with induction and consolidation 
chemotherapy in patients with newly diagnosed acute myeloid leukemia a total of 
19 patients were enrolled. Sixteen patients (84%) achieved a response; 14 (74%) 
composite complete response; 2 (11%) morphologic leukemia-free state. Most com-
mon grade 3/4 adverse events were febrile neutropenia (47%), neutropenia (42%), 
thrombocytopenia (32%), and anemia (26%). There were no apparent additional 
toxicities with addition of quizartinib to chemotherapy although grade ≤ 1 QT 
prolongation was observed at MTD [40]. In a large phase 2 trial assigning 333 (157 
in cohort 1 and 176 in cohort 2) r/r AML patients were enrolled. In cohort 1 56% 
of FLT3-ITD-positive patients and 36% of FLT3-ITD-negative patients achieved 
composite complete remission and in cohort 2 46% FLT3-ITD-positive patients 
achieved composite complete remission whereas 30% of FLT3-ITD-negative 
patients achieved composite complete remission. Across both cohorts the most 
common grade 3 or worse treatment-related adverse events were febrile neutro-
penia, anaemia, thrombocytopenia, QTcF prolongation, neutropenia, leucopenia 
thrombocytopenia and pneumonia [41]. Preliminary results of a randomized phase 
3 study (QuANTUM-R) in patients with FLT3-ITD mutated r/r AML enrolled 367 
patients, randomized 2:1 to receive quizartinib or 1 of 3 preselected investigator’s 
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choice therapy.(low-dose cytarabine, mitoxantrone, etoposide, and intermediate-
dose cytarabine or fludarabine, cytarabine, and granulocyte-colony stimulating 
factor with idarubicin). The results showed a significantly improved median OS for 
quizartinib (6.2 vs. 4.7 months; p = 0.017) and an improved cCR rate (48% vs. 27%, 
p = 0.0001). Rates of treatment-emergent adverse events were comparable between 
the 2 arms [42].
1.1.1.2.2 Crenolanib
Crenolanib (CP868596) is a benzamidine quinolone derivative, a second gen-
eration RTK inhibiting FLT3-ITD and -TKD mutations. It is potent, selective, and 
invulnerable to resistance-conferring kinase domain mutation. As a type I pan-
FLT3 inhibitor crenolanib inhibits FLT3/WT, FLT3/ITD, FLT3-TKD, PDGFRα/β, 
KIT, and FLT3/D835 [43]. In nearly one third of AML patients treated with FLT3 
inhibitors in different clinical trials a resistance point mutations like D835 and F691 
are occurring during disease progression [44, 45]. As a more potent RTK inhibitor 
crenolanib could inhibit both FLT3/ITD and resistant FLT3/D835 mutants and less 
disruptive of erythroid colony growth, which may result in relatively lessmyelosup-
pression [46]. In a phase 1 trial of FLT3-ITD positive AML crenolanib was given to 
69 patients divided in three cohorts, cohort A patients with R/R FLT3 AML who 
had not received prior FLT3 inhibitors, cohort B patients progressing on prior TKIs 
and cohort C patients who developed FLT3 + AML after prior MDS. Crenolanib 
therapy resulted in a 39% CRi and 11% PR (6 D835, 9 ITD, 3 ITD + D835) amongst 
the patients in cohort A with an ORR of 50% [47]. In a phase II trial, the tolerability 
and efficacy of crenolanib combined with standard 7 + 3 induction chemotherapy 
was examined in 29 patients with newly diagnosed FLT3 mutant AML. 21 of 29 
(72%) patients achieved a CR after one cycle of induction with cytarabine/anthra-
cycline/crenolanib. An additional 3 patients achieved a CR either after re-induction 
(1 patient) or after treatment with HiDAC or HSCT (1 patient each) [48]. In another 
study with the same inclusion criteria in which 26 patients were enrolled the most 
common advere events which led to crenolanib dose reductions were periorbital 
edema, delayed count recovery, LFT elevation, nausea and rash [49]. Also creno-
lanib was investigated in a patients with a first relapsed/primary refractory AML. 
The study enrolled 8 patients, received HAM followed by crenolanib. 6 patients 
were evaluable for responses with a complete remission rate of 67% (2 CR, 2 CRi), 
including 2 pts who were refractory to front line chemotherapy. 2 of 3 patients 
with FLT3 activating mutations (1 with ITD and 1 with D835) achieved complete 
remission with complete count recovery; the third pt (FLT3-ITD) had 10% residual 
blasts after 1 cycle of induction [50]. Ohanian et al. studied the effect of crenolanib 
combined with idarubicin and high-dose Ara-C in 13 pts (median age of 51 years) 
with multiply relapsed/refractory FLT3+ AML. The ORR in 11 pts evaluable for 
response was 36% (1 CR, 3 CRi; 2 not evaluable because of early discontinuation 
of therapy). The median OS for all patients was 259 days; median OS by prior 
therapies was 259 days for patients with ≤2 prior therapies, and 53 days for patients 
with ≥3 prior therapies. No dose-limiting toxicities were observed at any of the 
dose levels explored and there were no dose reductions required. Non-hematologic 
adverse events assessed as possibly or probably related to crenolanib were all grade 1 
in severity, including: nausea, vomiting, diarrhea, and abdominal pain [51].
1.1.1.2.3 Gilteritinib
Gilteritinib (ASP2215) is a selective next-generation novel dual FLT3 (to a 
lesser extent to FLT3-TKD than -ITD)/AXL inhibitor. Gilteritinib was investigated 
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in 252 patients with relapsed or refractory acute myeloid leukaemia in one of seven 
dose-escalation (n = 23) or dose-expansion (n = 229) cohorts. At least 90% of 
FLT3 phosphorylation inhibition was seen by day 8 in most patients receiving a 
daily dose of 80 mg or higher. In the full analysis 249 patients were included, 8% 
achieved complete remission, 4% complete remission with incomplete platelet 
recovery, 18% complete remission with incomplete haematological recovery, and 
10% partial remission. The most common grade 3–4 adverse events irrespective of 
relation to treatment were febrile neutropenia (39%), anaemia (24%), thrombo-
cytopenia (13%), sepsis (11%), and pneumonia (11%) [52]. In another open-label 
phase 1 study in 24 Japanese patients with relapsed/refractory acute myeloid leuke-
mia the ORR among patients with mutated FLT3 was 80% and among FLT wild-
type was 36.4%. The MTD was 200 mg/d, dose-limiting toxicities were grade 3 
tumor lysis syndrome and grade 3 elevated blood lactate dehydrogenase, amylase, 
blood creatine phosphokinase levels, and syncope [53]. The phase 3 ADMIRAL 
trial assessing oral gilteritinib 120 mg per day versus salvage chemotherapy in 
adult r/r FLT3 mutated AML patients led to an FDA approval for gilteritinib. 369 
adults with FLT3 mutated AML in first relapse or refractory to front-line therapy 
were enrolled. The 21% of patients who achieved had a median time to response of 
3.6 months [54].
1.1.1.2.4 Cabozantinib
Cabozantinib is an oral tyrosine kinase inhibitor of multiple receptor tyrosine 
kinases and exhibits anti-tumor activity in several cancers [55, 56]. It inhibits FLT3, 
MET, AXL, vascular endothelial growth factor receptor, and KIT. In a study among 
18 patients with relapsed/refractory AML, 5 harboring FLT3/ITD mutations no 
patients had a marrow response according to formal criteria. 4 patients had periph-
eral blast reductions, 2 of these 4 patients transiently cleared circulating blasts, 
1 patient experienced a reduction in marrow blasts, and 1 had stable disease [57] 
(Table 1).
1.2  Mutations in epigenetic modifiers: regulators of DNA methylation and 
chromatin modification drugs
1.2.1 IDH inhibitors
For the first time IDH1 mutations in AML were identified in 2009 by sequenc-
ing an acute myeloid leukemia genome. IDH is an enzyme that catalyzes the 
oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG). 5-methylcy-
tosine (5mC) coverts to 5-hydroxymethylcytosine (5hmc) as a result of interaction 
between α-KG and TET2 which promotes DNA and histone demethylation [58]. 
Approximately 8–19% of AML cases carry IDH2 mutations, with another 7–14% 
carrying IDH1 mutations [59]. IDH1/2 are found with higher frequency in older 
patients and patients with a normal karyotype [60, 61]. IDH1 mutations almost 
exclusively occur at R132 while IDH2 involve substitutions at R140 or R172 [62]. 
While IDH2-R172 may represent a distinct genomic subgroup, which mutual 
exclusivity with NPM1 and with a distinct DNA methylation profile [63]. Some 
studies showed that IDH1 and IDH2-R172 mutation may predict a worse clinical 
outcome especially in CN-AML, while the IDH2-R140 concomitant NPM1 muta-
tion may be associated with better prognosis in AML [63–65]. More further studies 
are needed due to the conflicting data about the prognostic impact of IDH1/2 
mutations in AML.
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1.2.1.1 Enasidenib
Enasidenib (AG-221) is the first oral IDH mutation–specific inhibitor. It is a 
bivalent inhibitor of R140Q and R172K mutated IDH2 and induces terminal differ-
entiation of leukemic blasts into neutrophils in vivo [66]. IDH2 inhibitor enasidenib 
(AG-221/CC-90007) showed promising activity as a single agent in patients with 
mutated IDH2 in first-in-human phase 1/2 study with 345 patients enrolled. Median 
age was 68 years. 214 of 345 patients (62%) with relapsed or refractory (R/R) AML 
received enasidenib, 100 mg/d. 19.6% attained complete remission, 10.3% pro-
ceeded to an allogeneic bone marrow transplant, and the overall response rate was 
38.8%. 43.1% red blood cell transfusion–dependent and 40.2% platelet transfusion–
dependent patients achieved transfusion independence. Response and survival 
were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Among 
all 345 patients, the most common grade 3 or 4 treatment-related adverse events 
were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation 
Drug Class Mechanism of action Agent
Signaling and kinase pathway mutations 
inhibitors (FLT3 tyrosine kinase inhibitors)











Mutations in epigenetic modifiers: Regulators 
of DNA methylation and chromatin 
modification drugs (IDH inhibitors)
Inhibition of IDH2 Enasidenib
Inhibition of IDH1 Ivosidenib
Pro-apoptotic agents (Bcl-2 inhibitors) Inhibition of BCL2 Venetoclax
Hedgehog Inhibition (Smoothened 
inhibitors)





Polo-like kinase inhibitors Inhibition of Plk1 Volasertib
E-selectin inhibitors Inhibition of E-selectin Uproleselan
Checkpoint inhibitors Inhibition of PD-1 Nivolumab
Pembrolizumab
Inhibition of CTLA-4 Ipilimumab
CD33-targeted therapy Inhibition of CD33 Gemtuzumab Ozogamicin
Vadastuximab talirine
Table 1. 
Selected AML targeted agents.
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syndrome (6%) [67]. These results led to the FDA approval of enasidenib in 
r/r IDH2 mutated AML patients on 1 August 2017. With regard to predictors of 
response, the IDH2 mutation allele burden at study entry had no effect on response 
rate [66]. In a open-label, multicenter, phase 1 study patients 134 newlydiagnosed 
mIDH1 or mIDH2 AML were treated with induction therapy in combination with 
either ivosidenib 500 mg once daily (for mIDH1) or enasidenib (mIDH2) 100 mg 
daily. Among the 77 enasidenib-treated patients evaluable for efficacy, a response 
of CR, CRi, or CRp was achieved in 73% patients with de novo AML and in 63% 
patients with sAML. The most frequent co-occurring baseline mutations for 
patients with IDH2 mutations were DNMT3A, SRSF2 and ASXL1 [68].
1.2.1.2 Ivosidenib
Ivosidenib (AG-120) is a potent and selective IDH1 mutation small-molecule 
inhibitor. In phase 1, multicenter, open-label, dose-escalation and dose-expansion 
study 258 patients received ivosidenib orally, daily, in 28-day cycles. In the primary 
efficacy population (125 patients), the rate of complete remission or complete 
remission with partial hematologic recovery was 30.4%, the rate of complete 
remission was 21.6% and the overall response rate was 41.6%. The median durations 
of these responses were 8.2 months, 9.3 months, and 6.5 months, respectively. No 
residual detectable IDH1 mutations on digital polymerase-chain-reaction assay 
were detected in 21% patients who had a complete remission or complete remission 
with partial hematologic recovery. The most common adverse events (in ≥20% of 
the patients), irrespective of a relationship to ivosidenib, were diarrhea, leukocyto-
sis, febrile neutropenia, nausea, fatigue, dyspnea, prolongation of the QT interval. 
Peripheral edema, anemia, pyrexia, cough and and differentiation syndrome [69]. 
The results of this study led to the FDA approval of ivosidenib in r/r IDH1 mutated 
AML patients on 2 may 2019. Prescribing information contains a boxed warning 
about the risk of differentiation syndrome which may be life-threatening or fatal. 
In a open-label, multicenter, phase 1 study patients 134 newlydiagnosed mIDH1 
or mIDH2 AML were treated with induction therapy in combination with either 
ivosidenib 500 mg once daily (for mIDH1) or enasidenib (mIDH2) 100 mg daily. 
Among the 41 ivosidenib-treated patients evaluable for efficacy, a response of CR, 
CRi or CRp was achieved in 93% patients with de novo AML and 46% patients 
with sAML. Twenty-one patients received ≥1 cycle of consolidation therapy and 11 
patients received maintenance after consolidation. Seventeen patients proceeded to 
HSCT. For patients with IDH1 mutations the most frequent co-occurring baseline 
mutations were DNMT3A, NPM1 and NRAS. MRD-negative CRs using flow cytom-
etry were observed in 89% of patients with IDH1 positive mutational status [68].
1.3 Pro-apoptotic agents
1.3.1 Bcl-2 inhibitors
Bcl-2 gene is located on chromosome 18q21.33 and it was discovered in 1985 
through cloning the breakpoint of a translocation of t(14;18) found in follicular 
B lymphomas [70]. Bcl-2 is an integral protein of the mitochondrial membrane 
but has also been identified on endoplasmic reticulum and the nuclear envelope 
[71]. BCL2 family members are classified into pro and anti-apoptotic proteins. The 
anti-apoptotic BCL2 family contains 4 proteins: BCL2, BCLXL, BCL-w, and MCL-
1. Through direct activation of the effector proteins or antagonizing the effect of 
antiapoptotic proteins the pro-apoptotic proteins lead to an activation of caspase 
proteases [72]. Bcl 2 has proven to be major negative regulator in apoptosis, playing 
9
Target Therapy in Acute Myeloid Leukemia
DOI: http://dx.doi.org/10.5772/intechopen.94422
key roles in neoplastic transformation and leukemogenesis [73]. Overexpression of 
anti-apoptotic BCL2 proteins such as BCL2, BCL2L1 and MCL1 is widely associated 
with tumour initiation, progression and chemo resistance in AML [74].
1.3.1.1 Venetoclax
Venetoclax (ABT-199/GDC- 0199) is a highly selective oral BCL2 inhibitor and 
does not show significant BCL-XL antagonism [75]. Venetoclax induces apoptosis 
in AML cell lines, in-vitro patient samples and in mouse xenograft models [75, 
76]. In a phase II, single-arm study in 32 patients with high-risk relapsed/refrac-
tory AML or unfit for intensive chemotherapy venetoclax was given at a dose of 
800 mg daily. The overall response rate was 19%, an additional 19% of patients 
demonstrated antileukemic activity not meeting IWG criteria (partial bone mar-
row response and incomplete hematologic recovery). Twelve (38%) patients had 
IDH 1/2 mutations, of whom 4 (33%) achieved complete response or complete 
response with incomplete blood count recovery. The responses median progression 
free interval was 2.5 months. Common adverse events included nausea, diarrhea, 
febrile neutropenia and hypokalemia. Due to potential tumour lysis syndrome as 
seen in chronic lymphocytic leukemia, a daily dosing ramp up of venetoclax was 
executed until 800 mg per day [77]. More effective results were achieved in stud-
ies where venetoclax was combined with either low-dose cytarabine (LDAC) or 
hypomethylating agents (HMAs). In a phase Ib/II study in previously untreated 
patients with AML venetoclax was combined with low-dose cytarabine in 82 adults 
60 years or older. The median age was 74 years, 49% had secondary AML, 29% had 
prior HMA treatment, and 32% had poor-risk cytogenetic features. 54% achieved 
complete remission (CR)/CR with incomplete blood count recovery. The median 
OS was 10.1 months (95% CI, 5.7 to 14.2), and median duration of response (DOR) 
was 8.1 months (95% CI, 5.3 to 14.9 months). Early (30-day) mortality was 6% [78]. 
In another phase 1b study of venetoclax plus decitabine or azacitidine in untreated 
AML patients ≥65 years ineligible for standard induction therapy 145 patients were 
enrolled. Median age was 74 years, with poor-risk cytogenetics in 49% of patients. 
With a median time on study of 8.9 months, 67% of patients (all doses) achieved 
complete remission (CR) + CR with incomplete count recovery (CRi), with a 
CR + CRi rate of 73% in the venetoclax 400 mg + HMA cohort. No tumor lysis 
syndrome was observed. Common adverse events (>30%) included nausea, diar-
rhea, constipation, febrile neutropenia, fatigue, hypokalemia, decreased appetite, 
and decreased white blood cell count [79]. Due to these marked results venetoclax 
received FDA approval for combination with low dose cytarabine and HMAs. 
DiNardo et al. assessed the safety and efficacy of venetoclax in combination with 
FLAG-IDA in a heavily pre-treated r/r AML patients. Study included 12 patients, 
of 11 patients, 8 patients (73%) achieved a best response of CR/CRi (7 CR, 1 CRi) 
with a 6-month survival rate of 67%. Of the 8 responding patients, three patients 
proceeded to allogeneic SCT [80].
1.4 Hedgehog inhibition
1.4.1 Smoothened inhibitors
The Hedgehog (Hh) family of proteins control cell growth and survival. The 
Hedgehog signalling pathway (HhP) is essential for embryonic development 
and usually silenced in adult tissues. Germline mutations that subtly affect Hh 
pathway activity are associated with developmental disorders, whereas somatic 
mutations activating the pathway have been linked to multiple forms of human 
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cancer [81–83]. Aberrant activation of the HhP has been implicated in the main-
tenance of leukaemia stem cells in several model systems. Overexpression of 
various HH/GLI components have been found in chemotherapy resistant myeloid 
blasts and subsequent inhibition of the HH/GLI pathway revised the sensitivity to 
 chemotherapy [84, 85].
1.4.1.1 Glasdegib
Glasdegib (PF-913) is an oral, potent, selective, small molecule inhibitor of 
HH/GLI signalling, which binds to the smoothened (SMO) receptor [86]. In 
vitro treatment with Glasdegib induced a decrease in the quiescent cell popula-
tion and in vivo treatment attenuated the leukemia-initiation potential of AML 
cells in a serial transplantation mouse model [87]. An open-label, dose-finding, 
phase 1 study of glasdegib in 47 adult patients with myeloid malignancies 
(AML, n = 28) found 400 mg once daily as the MTD and a minor response was 
achieved (over 25% decrease from baseline in BM blasts) or better in more than 
30% of AML patients. The most common treatment-related adverse events 
included dysgeusia, decreased appetite, and alopecia [88]. Based on this study 
a phase II, randomized, open-label, multicenter study evaluated the efficacy of 
glasdegib plus low-dose cytarabine (LDAC) in patients with AML or high-risk 
myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 
100 mg was administered orally in 28-day cycles. Eighty-eight and 44 patients 
were randomized to glasdegib/LDAC and LDAC, respectively. Median overall 
survival was 8.8 (6.9–9.9) months with glasdegib/LDAC and 4.9 (3.5–6.0) months 
with LDAC. Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and 
LDAC arms, respectively, achieved complete remission (P < 0.05) [89]. Based on 
this study the FDA approved glasdegib in combination with low dose cytarabine 
for AML patients unfit for IC. Another phase-II study to evaluate glasdegib 
from day 3 plus standard-induction chemotherapy for untreated and fit AML 
or high-risk MDS patients revealed that 46.4% of patients achieved CR. Among 
all 69 patients, median OS was 14.9 (80% CI 13.4–19.3) months, with 12-month 
survival probability 66.6%. The most common treatment-related adverse events 
(≥50% patients) were diarrhea and nausea [90].
1.4.1.2 Sonidegib
Sonidegib (LDE225) is a specific SMO inhibitor and in refractory AML cells 
increased cell apoptosis and the efficacy of Adriamycin against tumor cells and 
lowered the expression of the targeted protein [91]. In a phase I/Ib study of 
azacitidine and sonidegib in myeloid malignancies the best response outcome for 
untreated AML/MDS patients was 23.1% and for rel/ref 7.1%. However, the rate 
of SD was remarkably high particularly in the rel/ref AML population at 76%. 
The most common Gr 3/4 AEs were: thrombocytopenia, neutropenia, anemia and 
leukopenia [92].
1.4.1.3 Vismodegib
Vismodegib (GDC-0449) safety and efficacy were evaluated in a phase Ib trial 
in patients with relapsed/refractory acute myeloid leukaemia. All enrolled patients 
had received prior cancer therapy; most had received more than one therapy, 
including hypomethylating agents, immunomodulators and targeted signalling 
pathway inhibitors. 38 received at least one dose of vismodegib but the study was 
terminated by the sponsor because of lack of efficacy [93].
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1.5 Polo-like kinase inhibitors
Polo-like kinases (Plks) are a family of 5 highly conserved serine/threonine pro-
tein kinases. They play a key role in mitotic checkpoint regulation and cell division. 
Plk1 has been shown to be overexpressed in a range of human cancers, including 
non-small cell lung cancer, prostate, ovarian, breast, and colorectal cancer as well 
as AML [94–96].
1.5.1 Volasertib
Volasertib (BI 6727) is a low-molecular-weight, adenosine triphosphate–com-
petitive kinase inhibitor that potently inhibits Plk1 [97]. In a randomized, phase 1/2, 
open-label, multicenter trial of low-dose cytarabine with or without volasertib in 
patients with AML ineligible for intensive induction therapy eighty-seven patients 
(median age 75 years) received LDAC or LDAC + volasertib. The result confirmed 
greater clinical efficacy in the combination arm, statistically significant in CR (30 
vs. 13.3%, P = 0.052). Median overall survival was 8.0 vs. 5.2 months, respectively. 
LDAC + volasertib led to an increased frequency of adverse events that was most 
pronounced for neutropenic fever/infections and gastrointestinal events [98].
1.6 E-selectin inhibitors
The endothelial cell adhesion molecule E-selectin is a key component of the bone 
marrow hematopoietic stem cell (HSC) vascular niche regulating balance between 
HSC self-renewal and commitment. E-selectin is expressed transiently in the 
normal vasculature during an inflammatory response and constitutively in the bone 
marrow. E-selectin directly triggers signaling pathways that promote malignant 
cell survival and regeneration. In vivo AML blasts with highest E-selectin binding 
potential are 12-fold more likely to survive chemotherapy and main contributors to 
disease relapse [99, 100].
1.6.1 Uproleselan
Uproleselan (GMI-1271) is a novel antagonist of E-selectin that down-regulates 
cell survival pathways and enhances chemotherapy response. In a single arm phase 
I/II trial of 47 adults with relapsed/refractory AML were treated with GMI-1271 in 
combination with MEC chemotherapy. GMI-1271 was given 24 hrs prior, then every 
12 hrs during and for 48 hrs post induction/consolidation. With a median follow-up 
of 11 months, the ph 1 median leukemia free survival was not reached and overall 
survival was 7.6 months. ORR (CR/CRi/MLFS/PR) was evaluable in 21 patients 
was 50%. Remission rate (CR/CRi) was 45%.Common Gr 3/4 AEs were febrile 
neutropenia, sepsis, bacteremia, hypoxia. 30 and 60 day mortality were 0 and 7%, 
respectively [101]. A pivotal phase 2/3 study (NCT03616470) is underway to assess 
the efficacy and safety of uproleselan with standard salvage chemotherapy in R/R 
AML. The study is a global, randomized, double-blind, phase 3 trial in adults aged 
18–75 years with R/R AML and fit for chemotherapy [102].
1.7 Checkpoint inhibitors
The development of immune checkpoint inhibitors (ICIs) is a revolutionary 
milestone in the field of immuno-oncology. Immune checkpoint blockade removes 
inhibitory signals of T-cell activation, which enables tumor-reactive T cells to over-
come regulatory mechanisms and mount an effective antitumor response [103–105]. 
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Recent studies suggest a novel mechanism that tumor cells might evade host 
immune attack through increased expression of PD-L1 [106]. Immune checkpoint 
inhibitor treatment involves programmed cell death protein 1 (PD1) and cytotoxic 
Tlymphocyte- associated antigen 4 (CTLA4), both of which have been used in 
preclinical AML models [107].
1.7.1 Nivolumab
Nivolumab (BMS-936558, ONO-4538, or MDX1106) is the first-in-human 
immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that 
disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, 
thereby inhibiting the cellular immune response [108, 109]. In a phase IB/II study 
of nivolumab in combination with azacytidine in patients (pts) with relapsed AML 
51 patients with a median age of 69 years (range 45–90) were included. From 35 
patients evaluable for response, 6 (18%) achieved complete remission (CR)/(CRi) 
(3 CR, 3 CRi), 5 (15%) had hematologic improvement (HI), 9 (26%) had 50% 
BM blast reduction,3 pts. (9%) had stable disease >6 months, and 12 (34%) had 
progression. In the subgroup of patients who did not receive HMA prior treatment, 
the superiority of new regimen was even more evident with ORR at 52–22%. The 
median overall survival for the 35 evaluable pts was 9.3 months (range, 1.8–14.3). 
Grade 3/4 and Grade 2 immune mediated toxicities were observed in 7 (14%) and 
6 (12%) patients, which included pneumonitis, nephritis, transaminitis, and skin 
rash. Steroids took effect on 88% of the patients who suffered from drug-related 
toxicities [110]. A single-arm, phase 2 part of the phase 1–2 study of nivolumab in 
combination with idarubicin and cytarabine was conducted in 44 patients with 
newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. 
The median overall survival was 18.54 months and median event-free survival was 
not reached. Among the 44 evaluable patients, the ORR was 77% including 63% 
CR and 14% CRi. Concerning drug toxicities, the grade 3–4 adverse events were 
observed in six patients, including rash, colitis, pancreatitis and transaminitis [111]. 
Using nivolumab in post-transplantation setting showed limited efficacy. Among 
three relapsed AML patients after allo-HSCT treated with nivolumab, one achieved 
CR, one experienced stabilization, and the third failed to respond [112].
1.7.2 Pembrolizumab
Pembrolizumab (MK-3475) is another drug that blocks PD-1. In a multicenter 
phase II study pembrolizumab was administered after high-dose cytarabine salvage 
chemotherapy in 26 R/R AML patients with median age of 54. The overall response 
rate was 42% with 9 CR/CRi, one PR, and one patient with morphologic leukemia 
free state. The median OS was 10.5 months. Most frequently observed grade 3 AEs 
included hepatitis, rash, and epigastric pain [113]. In another single center, single 
arm trial of pembrolizumab followed by decitabine in 10 patients R/R AML patients 
with median age of 62, the ORR was 20% with one patient achieving MRD-negative 
CR. With a median follow-up of 13 months, the mOS was 7 months [114].
1.7.3 Ipilimumab
Ipilimumab is a human IgG1 monoclonal antibody, CTLA-4 antagonist. In a 
phase I/Ib, open label, multicenter study of treating patients with relapsed hemato-
logical malignancies after allo-SCT with ipilimumab 12 AML patients were enrolled. 
Complete response was observed in five patients (23%) and the 1-year survival rate 
was 49%. Immune-related adverse events occurred in three patients. Response was 
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associated with in situ infiltration of CD8+ T cells as well as enrichment of effector 
T cell subsets [115].
1.8 CD33-targeted therapy
The CD33 antigen is expressed on the blast cells (85–90%) of most cases of acute 
myeloid leukemia [116–118]. CD33 seems to be much less expressed on normal 
hematopoietic stem cells and has decreased expression during the differentiation 
of the myeloid lineage. Mature granulocytes do not express a significant amount 
of CD33. That makes CD33 an promising target for AML targeted therapy [119, 
120]. The only non-haematopoietic cells expressing CD33 are hepatocytes, which 
explains to some extent hepatic toxicity induced by anti CD33 antibodies [121, 122].
2. Gemtuzumab ozogamicin (GO)
Gemtuzumab ozogamicin (Mylotarg) is a humanized anti-CD33 IgG4 mono-
clonal antibody conjugated to a cytotoxic agent N-acetyl gamma calicheamicin via 
an acid-labile hydrazone linker. After GO binds to CD33, calicheamicin is being 
released and generates single and double strand breaks with subsequent cellular 
death [123]. In a phase I dose escalation study of an anti-CD33 calicheamicin 
immunoconjugate 40 patients with relapsed or refractory CD33(+) AML were 
treated. Leukemia was eliminated from the blood and marrow of 8 (20%) of the 
40 patients and the MTD was determined to be 9 mg/m2 [124]. After the encourag-
ing results from three open label phase II studies, the FDA approved GO for the 
treatment of patients with CD33-positive AML in first relapse who were ≥ 60 years 
and not suitable for intensive chemotherapy. 142 patients with AML in first relapse 
were enrolled in the studies with median age of 61 years. All patients received 
Mylotarg as a 2-hour intravenous infusion, at a dose of 9 mg/m2, at 2-week intervals 
for two doses. 30% of patients obtained complete morphological remission. High 
incidences of myelosuppression, grade 3 or 4 hyperbilirubinemia, and elevated 
hepatic transaminase levels were registered [125]. In a post-approval phase III trial 
gemtuzumab ozogamicin was administred during induction and postconsolidation 
therapy in younger patients with acute myeloid leukemia. 637 patients were ran-
domly assigned to receive daunorubicin, cytarabine, and GO vs. standard induction 
therapy with daunorubicin and cytarabine alone. The CR rate was 69% for DA + GO 
and 70% for DA (P = 0.59). In this study, the addition of GO to induction or post-
consolidation therapy failed to show improvement in CR rate, disease-free survival, 
or overall survival. Also addition of GO was associated with a higher early mortality 
during induction (5.5% vs. 1.4%). Major causes of death were fatal hemorrhage 
and infection. Based on these negative results GO was withdrawn from the market 
in 2010 [126]. In a subsequent trials different schedules of GO were investigated. 
Phase 3, open-label study enrolled 280 patients aged 50–70 years with previously 
untreated de novo AML. Patients were randomly assigned in a 1:1 ratio to standard 
treatment (control group) with or without five doses of intravenous gemtuzumab 
during induction and day 1 of each of the two consolidation chemotherapy courses. 
Although the CR rates were similar between the two arms, IC plus GO provided 
a significantly improved median event free survival (EFS) (19.6 vs. 11.9 months, 
p = 0.00018) and median OS (34 vs. 19.2 months, p = 0.046). Haematological 
toxicity, particularly persistent thrombocytopenia, was more common in the GO 
group than in the control group, without an increase in the risk of death from toxic-
ity [127]. A meta-analysis of five open label, phase 3 trials comprising 3325 AML 
patients found that the addition of gemtuzumab ozogamicin significantly reduced 
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the risk of relapse and improved overall survival at 5 years without increased 
toxicity for GO treatment [128]. Based on these results FDA approved GO for the 
treatment of adults with newly diagnosed CD33-positive AML on 1 September 2017, 
and also approved Mylotarg for the treatment of patients aged 2 years and older 
with relapsed or refractory CD33-positive AML.
3. Vadastuximab talirine
Vadastuximab talirine (SGN-CD33A) is a novel anti-CD33 mAb conjugated to 
2 molecules of pyrrolobenzodiazepine (PBD). After internalization vadastuximab 
where transported to the lysosomes where the PBD dimer is released via proteolytic 
cleavage of the linker, crosslinking DNAand leading to apoptosis. Vadastuximab is 
highly stable in circulation with relatively less off-target toxicity compared to GO 
[129]. In a dose-escalation phase 1 study 27 treatment naive patients with CD33 
positive AML and median age of 74 years were treated with vadastuximab talirine. 
Of the 26 efficacy evaluable treatment naive patients, 6 patients achieved CR, 8 
patients CRi, and 5 patients achieved a morphologic leukemia-free state [130]. In 
another phase 1 trial of vadastuximab talirine as monotherapy in patients with 
CD33-positive AML a total of 131 patients, median age, 73 years were enrolled. The 
CR + CRi rate was 28%, 50% of patients who responded achieved minimal residual 
disease negativity. Most AEs were consistent with myelosuppression, nonhema-
tological included fatigue, nausea, and diarrhea [131]. Also vadastuximab talirine 
was added to a 7 + 3 induction therapy in a phase 1b study in 42 patients with a 
median age of 45.5 years. The CR/CRi rate was 78%. Twenty-three of 31 (74%) 
patients attaining CR or CRi achieved MRD negative status. No 30-day mortality or 
significant hepatotoxicity was observed [132]. Fathi et al. combined vadastuximab 
talirine with hypomethylating agents in patients with CD33-positive AML. Among 
53 patients treated, the median age was 75 years. The CR + CRi rate was 70% and 
51% of remissions with minimal residual disease-negative status by flow cytometry. 
The majority of adverse events were a result of myelosuppression, with some caus-
ing therapy delays [133]. A phase III trial (CASCADE, NCT02785900) comparing 
HMA with or without SGN-CD33A in elderly patients with newly diagnosed AML 
was terminated because of due to safety reasons, specifically a higher rate of deaths, 
including fatal infections, in the SGN33A arm versus the control arm.
4. Future perspectives
The great advances in understanding molecular mechanisms of AML as well as 
their prognostic significance have changed the therapeutic armamentarium against 
AML. The drugs discussed in this chapter and many novel molecules being evalu-
ated in clinical trials are on their way to change the current standard of treatment 
in AML. Ongoing efforts to understand the heterogeneity of AML, the constantly 
changing genomic landscape, the mechanisms of resistance/refractoriness will be 
very important in the development of new drugs. The rational use of these drugs, 
their potency that might be improved by combining them with other modes of ther-
apy will hopefully increase long-term benefits for patients with AML. Furthermore, 
the development of novel ultrasensitive methods for minimal residual disease 
detection will also refine the treatment decision making process and probably 
improve the survival rates. However, new issues such as extrapolation of the results 
from the clinical trials enrolling carefully selected patients to general practice, the 
access and cost of these new drugs must be considered in the treatment decision 
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process. It is a question of time whether personally tailored therapeutic era is going 
to be the new standard in the treatment of AML. Till then an increased enrolment 
of patients with AML into clinical trials evaluating the safety and efficacy of these 
new drugs and combinations is strongly encouraged and recommended.
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